Crispr Therapeutics AG (NASDAQ:CRSP) was the recipient of a significant decrease in short interest during the month of December. As of December 13th, there was short interest totalling 3,400,000 shares, a decrease of 6.1% from the November 28th total of 3,620,000 shares. Based on an average daily volume of 1,000,000 shares, the short-interest ratio is presently 3.4 days. Currently, 9.9% of the company’s stock are sold short.

Shares of NASDAQ CRSP traded up $0.54 during midday trading on Tuesday, reaching $60.49. 696,648 shares of the company’s stock traded hands, compared to its average volume of 966,083. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. The company has a market cap of $3.36 billion, a price-to-earnings ratio of -17.58 and a beta of 3.20. The stock’s 50 day simple moving average is $66.14 and its 200-day simple moving average is $51.34. Crispr Therapeutics has a one year low of $29.34 and a one year high of $74.00.

Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, topping the consensus estimate of ($0.95) by $3.35. The business had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. Equities analysts predict that Crispr Therapeutics will post 0.65 EPS for the current fiscal year.

Several analysts have issued reports on CRSP shares. Roth Capital boosted their price target on Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. TheStreet raised shares of Crispr Therapeutics from a “d” rating to a “c” rating in a research note on Monday, October 28th. Wells Fargo & Co reissued a “buy” rating on shares of Crispr Therapeutics in a research note on Friday, December 6th. Goldman Sachs Group raised their target price on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the stock a “neutral” rating in a report on Tuesday, November 19th. Finally, Oppenheimer upped their price target on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a report on Monday, November 25th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and twelve have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $71.38.

In other news, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total transaction of $390,000.00. Following the transaction, the director now directly owns 7,500 shares of the company’s stock, valued at $390,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the sale, the president now directly owns 33,618 shares in the company, valued at $2,353,260. The disclosure for this sale can be found here. Insiders have sold 56,118 shares of company stock valued at $3,620,760 over the last three months. Insiders own 21.40% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Millennium Management LLC acquired a new position in Crispr Therapeutics during the third quarter worth $4,366,000. Orbimed Advisors LLC acquired a new stake in Crispr Therapeutics in the 3rd quarter valued at about $21,167,000. Granahan Investment Management Inc. MA boosted its stake in shares of Crispr Therapeutics by 8.3% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 34,582 shares of the company’s stock valued at $1,418,000 after buying an additional 2,655 shares during the period. Barclays PLC grew its position in shares of Crispr Therapeutics by 42.7% during the third quarter. Barclays PLC now owns 13,877 shares of the company’s stock worth $568,000 after buying an additional 4,151 shares in the last quarter. Finally, Stifel Financial Corp grew its position in shares of Crispr Therapeutics by 18.0% during the third quarter. Stifel Financial Corp now owns 9,795 shares of the company’s stock worth $400,000 after buying an additional 1,491 shares in the last quarter. 49.82% of the stock is currently owned by institutional investors and hedge funds.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Recommended Story: How can investors invest in the S&P/TSX Index?



Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.




Source link